Jadason Enterprises Ltd (SGX:J03)

Intra-Cellular Therapies Income Statement

Financials in millions SGD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	25.31	21.92	32.15	42.78	41.09
Revenue Growth (YoY)	15.43%	-31.81%	-24.85%	4.13%	-7.15%
Cost of Revenue	22.42	21.15	31.27	40.9	35.67
Gross Profit	2.89	0.77	0.88	1.89	5.42
Selling, General & Admin	4.22	5.59	8.15	9.64	9.33
Operating Expenses	4.27	5.68	8.15	9.64	9.33
Operating Income	-1.38	-4.91	-7.27	-7.75	-3.91
Interest Expense	-0.07	-0.24	-0.58	-0.82	-0.91
Interest & Investment Income	0.11	0.15	0.11	0.09	0.05
Currency Exchange Gain (Loss)	-0.75	-0.11	-0.66	-0.26	0.53
Other Non Operating Income (Expenses)	0.23	-0.42	0.58	0.88	0.85
EBT Excluding Unusual Items	-1.86	-5.53	-7.81	-7.87	-3.39
Merger & Restructuring Charges	-0.02	-0.45	-0.29	-	-
Gain (Loss) on Sale of Assets	0.06	0.03	0.54	0.02	0.06
Asset Writedown	-0.86	-2.32	-0.13	-2.86	-1.14
Other Unusual Items	1.66	0.3	0.75	0.09	0.56
Pretax Income	-1.02	-7.97	-6.94	-10.63	-3.9
Income Tax Expense	0.08	0	0.01	0.01	0.17
Net Income	-1.1	-7.97	-6.95	-10.64	-4.08
Net Income to Common	-1.1	-7.97	-6.95	-10.64	-4.08
Shares Outstanding (Basic)	722	722	722	722	722
Shares Outstanding (Diluted)	722	722	722	722	722
EPS (Basic)	-0.00	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.00	-0.01	-0.01	-0.01	-0.01
Free Cash Flow	-2.54	-0.07	-0.75	5.04	6.31
Free Cash Flow Per Share	-0.00	-	-0.00	0.01	0.01
Gross Margin	11.42%	3.51%	2.74%	4.41%	13.19%
Operating Margin	-5.45%	-22.39%	-22.61%	-18.12%	-9.51%
Profit Margin	-4.35%	-36.36%	-21.60%	-24.86%	-9.92%
Free Cash Flow Margin	-10.04%	-0.30%	-2.32%	11.79%	15.36%
EBITDA	-1.26	-4.8	-7.05	-6.86	-2.88
EBITDA Margin	-4.99%	-21.87%	-21.91%	-16.02%	-7.01%
D&A For EBITDA	0.12	0.11	0.22	0.9	1.03
EBIT	-1.38	-4.91	-7.27	-7.75	-3.91
EBIT Margin	-5.45%	-22.39%	-22.61%	-18.12%	-9.51%

Updated Aug 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.